论文部分内容阅读
目的 探讨子宫内膜细胞学在放置宫内节育器(intrauterine contraceptive device,IUD)中应用的临床价值。方法 对来深圳市龙岗区坂田街道计划生育服务中心放置IUD的300例妇女应用子宫内膜采集器采取子宫内膜样本进行检测。结果 满意标本292例,子宫内膜细胞学诊断结果未见异常231例(79.11%),良性增生性改变51例(17.47%),不典型增生10例(3.42%),未查见子宫内膜癌。年龄>35岁的妇女良性增生性改变发生率高于年龄≤35岁的妇女,差异有统计学意义(P<0.05);存在高危因素的妇女良性增生性改变发生率、不典型增生发生率均高于无高危因素者,差异有统计学意义(P<0.05)。放置IUD后,细胞学诊断未见异常人群的月经异常发生率、白带异常发生率均低于良性增生性改变人群,差异有统计学意义(P<0.05);未见异常人群月经异常发生率低于不典型增生人群,差异有统计学意义(P<0.05);下腹疼痛发生率无统计学意义(P>0.05)。结论 放置IUD时了解受术者的子宫内膜状态可以有效地指导进一步的处理和治疗,在计划生育临床服务工作上有着科学的指导性意义;同时也是子宫内膜癌筛查的有效检测手段,值得临床推广。
Objective To investigate the clinical value of endometrial cytology in intrauterine contraceptive device (IUD). Methods 300 women who had placed IUD in Family Planning Service Center, Bantian Street, Longgang District, Shenzhen City were tested by endometrial sampling with endometrial sampling. The results of satisfactory specimens 292 cases, no endometrial cytology diagnostic results in 231 cases (79.11%), benign hyperplastic changes in 51 cases (17.47%), atypical hyperplasia in 10 cases (3.42%), did not see the endometrium cancer. The incidence of benign prostatic hyperplasia in women> 35 years old was higher than that in women ≤35 years old (P <0.05). The incidence of benign prostatic hyperplasia and atypical hyperplasia in women with high risk factors Higher than no risk factors, the difference was statistically significant (P <0.05). After IUD placement, the incidence of menstrual abnormalities and leucorrhea abnormalities in the abnormal population were not significantly higher than those in benign hyperplasia (P <0.05). There was no significant difference in the incidence of abnormal menstruation Atypical hyperplasia, the difference was statistically significant (P <0.05); the incidence of abdominal pain was not statistically significant (P> 0.05). Conclusion It is of scientific guiding significance to understand the endometrial status of the patients when IUD is placed, which can effectively guide further treatment and treatment. It is also an effective means of screening endometrial cancer screening, Worth clinical promotion.